Enhancing Patient Retention in Clinical Trials-Strategies for Success.

[1]  S. Mandrekar,et al.  Rates of and Factors Associated With Patient Withdrawal of Consent in Cancer Clinical Trials. , 2023, JAMA oncology.

[2]  G. Sadigh,et al.  Introduction to the Focused Issue: Financial Toxicity and the Growing Affordability Crisis. , 2022, Journal of the American College of Radiology.

[3]  E. Eisenhauer,et al.  The Time Toxicity of Cancer Treatment. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Yue Cao,et al.  Comparing a Multimedia Digital Informed Consent Tool With Traditional Paper-Based Methods: Randomized Controlled Trial , 2020, JMIR formative research.

[5]  M. Terris,et al.  Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. , 2019, JAMA oncology.

[6]  C. Gamble,et al.  Reducing attrition within clinical trials: The communication of retention and withdrawal within patient information leaflets , 2018, PloS one.

[7]  David B. Fogel,et al.  Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review , 2018, Contemporary clinical trials communications.

[8]  P. Garrido,et al.  Patient involvement in clinical research: why, when, and how , 2016, Patient preference and adherence.

[9]  D. Cunningham,et al.  Patients’ willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey , 2016, Trials.

[10]  Juan Wisnivesky,et al.  Geographic accessibility to clinical trials for advanced cancer in the United States. , 2015, JAMA internal medicine.

[11]  Sonya Brownie,et al.  Patients' recollection and understanding of informed consent: a literature review , 2014, ANZ journal of surgery.

[12]  R. Kominski,et al.  Language Use in the United States: 2007 , 2010 .

[13]  L. Bazzano,et al.  A Modern History of Informed Consent and the Role of Key Information , 2021, Ochsner Journal.

[14]  M. Hansson,et al.  Hope for a cure and altruism are the main motives behind participation in phase 3 clinical cancer trials. , 2015, European journal of cancer care.